BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Summary by AI BETAClose X

BioNTech will present new clinical data for its lung cancer pipeline at the WCLC 2026 conference, including the first global data for the novel-novel combination of pumitamig with elfetabart drozuntecan in advanced or metastatic lung cancer. Updated overall survival data for gotistobart from the PRESERVE-003 Phase 3 trial in second- and later-line advanced squamous non-small cell lung cancer will also be shared, reinforcing its potential as a chemotherapy-free treatment. The company is advancing a broad lung cancer development program with over 16 ongoing clinical trials, including five Phase 3 trials and two novel-novel combination trials.

Disclaimer*

UK 100

Latest directors dealings